Evidence map›Paper›PMID 32344632›Full record

ArticleGenes2020

Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment.

Nikola Kotur, Jelena Lazic, Bojan Ristivojevic, Biljana Stankovic, Vladimir Gasic, Lidija Dokmanovic, Nada Krstovski, Goran Milosevic, Dragana Janic, Branka Zukic and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Exploratory Association of 5' and 3' UTRs Variants inInternational journal of molecular sciences · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Can Pharmacogenetic Variants inInternational journal of molecular sciences · 2023
    Article
  13. Article
  14. Article
  15. Review
  16. Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions.International journal of molecular sciences · 2021
    Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Nikola KoturLaboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444a, 11 000 Belgrade, Serbia.ORCID 0000-0002-9440-9258
Jelena LazicDepartment of Hematology and Oncology, University Children's Hospital, University of Belgrade, Tirsova 10, 11 000 Belgrade, Serbia.
Bojan RistivojevicLaboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444a, 11 000 Belgrade, Serbia.
Biljana StankovicLaboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444a, 11 000 Belgrade, Serbia.ORCID 0000-0002-7571-277X
Vladimir GasicLaboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444a, 11 000 Belgrade, Serbia.
Lidija DokmanovicDepartment of Hematology and Oncology, University Children's Hospital, University of Belgrade, Tirsova 10, 11 000 Belgrade, Serbia.
Nada KrstovskiDepartment of Hematology and Oncology, University Children's Hospital, University of Belgrade, Tirsova 10, 11 000 Belgrade, Serbia.
Goran MilosevicDepartment of Hematology and Oncology, University Children's Hospital, University of Belgrade, Tirsova 10, 11 000 Belgrade, Serbia.
Dragana JanicDepartment of Hematology and Oncology, University Children's Hospital, University of Belgrade, Tirsova 10, 11 000 Belgrade, Serbia.
Branka ZukicLaboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444a, 11 000 Belgrade, Serbia.
Sonja PavlovicLaboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444a, 11 000 Belgrade, Serbia.
University of Belgrade · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Methotrexate (MTX) is one of the staples of pediatric acute lymphoblastic leukemia (ALL) treatment. MTX targets the folate metabolic pathway (FMP). Abnormal function of the enzymes in FMP, due to genetic aberrations, leads to adverse drug reactions. The aim of this study was to investigate variants in pharmacogenes involved in FMP and their association with MTX pharmacokinetics (MTX elimination profile) and toxicity in the consolidation therapy phase of pediatric ALL patients. Eleven variants in the thymidylate synthetase (

Indexed as

PharmacogeneticsPolymorphism, Single NucleotideAdolescentAntimetabolites, AntineoplasticBiomarkers, TumorChildChild, PreschoolDrug-Related Side Effects and Adverse ReactionsFemaleGene Expression Regulation, NeoplasticGenotypeHumansInfantMaleMethotrexatePrecursor Cell Lymphoblastic Leukemia-LymphomaAntimetabolites, AntineoplasticBiomarkers, TumorMethotrexatedrug-related toxicitymethotrexatepediatric ALLpharmacogenomicspharmacokinetics

Identifiers

PMID32344632
PMCPMC7230684
OpenAlexW3017480542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.